<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">plekhg5</th>
</tr>
<tr>
<td class="label">Domain</td>
<td>Position</td>
</tr>
<tr>
<td class="label">N-terminal Region</td>
<td>1-400</td>
</tr>
<tr>
<td class="label">coiled-coil</td>
<td>150-320</td>
</tr>
<tr>
<td class="label">PH (Pleckstrin Homology)</td>
<td>500-620</td>
</tr>
<tr>
<td class="label">Dbl-type RhoGEF</td>
<td>750-950</td>
</tr>
<tr>
<td class="label">C-terminal Region</td>
<td>1000-1954</td>
</tr>
<tr>
<td class="label">DUP (Domain of Unknown Function)</td>
<td>1400-1700</td>
</tr>
<tr>
<td class="label">Interactor</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">RhoA</td>
<td>GEF substrate</td>
</tr>
<tr>
<td class="label">Rac1</td>
<td>GEF substrate</td>
</tr>
<tr>
<td class="label">Cdc42</td>
<td>GEF substrate</td>
</tr>
<tr>
<td class="label">RhoG</td>
<td>GEF substrate</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a>, <a href="/wiki/motoneuron_disease" style="color:#ef9a9a">motoneuron_disease</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">19 edges</a></td>
</tr>
</table>
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">plekhg5</th>
</tr>
<tr>
<td class="label">Domain</td>
<td>Position</td>
</tr>
<tr>
<td class="label">N-terminal Region</td>
<td>1-400</td>
</tr>
<tr>
<td class="label">coiled-coil</td>
<td>150-320</td>
</tr>
<tr>
<td class="label">PH (Pleckstrin Homology)</td>
<td>500-620</td>
</tr>
<tr>
<td class="label">Dbl-type RhoGEF</td>
<td>750-950</td>
</tr>
<tr>
<td class="label">C-terminal Region</td>
<td>1000-1954</td>
</tr>
<tr>
<td class="label">DUP (Domain of Unknown Function)</td>
<td>1400-1700</td>
</tr>
<tr>
<td class="label">Interactor</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">RhoA</td>
<td>GEF substrate</td>
</tr>
<tr>
<td class="label">Rac1</td>
<td>GEF substrate</td>
</tr>
<tr>
<td class="label">Cdc42</td>
<td>GEF substrate</td>
</tr>
<tr>
<td class="label">RhoG</td>
<td>GEF substrate</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a>, <a href="/wiki/motoneuron_disease" style="color:#ef9a9a">motoneuron_disease</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">19 edges</a></td>
</tr>
</table>
Plekhg5 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
PLEKHG5 (Pleckstrin Homology And RhoGEF Domain Containing G5), also known as KIAA0724 or GEF c15, is a Rho guanine nucleotide exchange factor (RhoGEF) encoded by the PLEKHG5 gene located on chromosome 1p36.31 (NCBI Gene ID: 57410) [1]. This gene encodes a protein of approximately 1,954 amino acids with a molecular weight of ~213 kDa, functioning as a key regulator of Rho GTPase signaling and actin cytoskeleton dynamics [2]. PLEKHG5 is expressed predominantly in the nervous system, with highest expression in motor [neurons](/entities/neurons), cortical neurons, and peripheral nerve tissue [3]. [@umikawa1999]
PLEKHG5 plays critical roles in neuronal morphogenesis, axonal growth, synaptic plasticity, and myelination—all processes central to normal neurological function and vulnerable to degeneration in amyotrophic lateral sclerosis (ALS), Charcot-Marie-Tooth disease (CMT), and other neurodegenerative disorders [4]. Mutations in PLEKHG5 were first linked to autosomal recessive intermediate Charcot-Marie-Tooth disease type C (CMTRIC) in 2008, and subsequent studies have identified PLEKHG5 variants in ALS patients, establishing it as a disease gene for both peripheral neuropathy and motor neuron disease [5][6]. [@may2012]
The protein functions as a potent activator of Rho GTPases, particularly RhoA, Rac1, and Cdc42, through its Dbl-type RhoGEF domain [7]. By catalyzing the exchange of GDP for GTP, PLEKHG5 activates these molecular switches, triggering downstream signaling cascades that regulate actin polymerization, cell adhesion, microtubule dynamics, and gene expression [8]. In neurons, these signaling pathways are essential for axonal growth cone guidance, dendritic spine formation, and the maintenance of neuronal connectivity [9]. [@stendel2010]
--- [@auergrumbach2008]
The PLEKHG5 gene spans approximately 46 kb of genomic DNA on the plus strand of chromosome 1p36.31, comprising 33 exons that encode the full-length protein [1]. The gene exhibits complex alternative splicing, producing multiple transcript variants with distinct expression patterns and functional properties. The major transcript (NM_020631) encodes the canonical 1,954-amino acid protein, while alternative splicing generates isoforms with alternative N- or C-terminal sequences [2]. [@blitterswijk2012]
PLEKHG5 expression is dynamically regulated during development and in response to cellular signaling. The PLEKHG5 promoter contains binding sites for multiple transcription factors including SP1, AP-2, and [NF-κB](/entities/nf-kb), allowing integration of diverse cellular signals [10]. In neurons, PLEKHG5 transcription is activity-dependent, with synaptic activity and growth factor signaling enhancing PLEKHG5 expression through MAPK and PI3K pathways [11]. Epigenetic regulation also contributes to PLEKHG5 expression, with promoter methylation patterns correlating with expression levels in various tissues and disease states [12]. [@rossman2005]
--- [@etiennemanneville2002]
PLEKHG5 possesses a complex domain architecture characteristic of RhoGEF proteins, consisting of multiple functional domains that mediate protein-protein interactions and membrane localization [13]: [@govek2005]
The Dbl-type RhoGEF domain is the core catalytic module, catalyzing the exchange of GDP for GTP on Rho family GTPases [7]. This domain adopts a fold consisting of a six-helix bundle that interacts with the Switch I and Switch II regions of the GTPase, stabilizing the nucleotide-free state and accelerating GDP release [14]. The PH domain upstream of the RhoGEF domain promotes membrane association through phosphoinositide binding, positioning the enzyme near its substrate GTPases at the plasma membrane [15]. [@wang2006]
PLEKHG5 activity is regulated through multiple mechanisms. Autoinhibition occurs through intramolecular interactions between the N-terminal and C-terminal regions, which block the RhoGEF domain under basal conditions [16]. Activation requires relief of this autoinhibition through binding to phosphoinositides at the plasma membrane or through protein-protein interactions with regulatory partners [17]. Additional regulation occurs through post-translational modifications including phosphorylation (by Src family kinases and PKC) and ubiquitination, which modulate protein stability, localization, and activity [18]. [@ridley2012]
--- [@ridley2001]
PLEKHG5 is a potent activator of Rho family GTPases, with particular activity toward RhoA, Rac1, and Cdc42 [7]. These GTPases function as molecular switches, cycling between active GTP-bound and inactive GDP-bound states. PLEKHG5 catalyzes the rate-limiting GDP release step, effectively turning on these switches: [@etiennemanneville2000]
In neurons, PLEKHG5-mediated Rho GTPase signaling regulates critical processes: [@govek2005a]
Axonal Growth and Guidance: PLEKHG5 activates Rho GTPases in growth cones, directing actin cytoskeleton remodeling in response to guidance cues [22]. The balance between RhoA and Rac1/Cdc42 signaling determines whether growth cones advance, pause, or collapse in response to repulsive or attractive cues [23]. [@watermanstorer2003]
Dendritic Spine Morphogenesis: Postsynaptic PLEKHG5 regulates spine shape and size through Rac1-dependent actin polymerization [24]. PLEKHG5 activity is required for activity-dependent spine enlargement during learning-related plasticity [25]. [@tashiro2000]
Synaptic Plasticity: PLEKHG5 participates in [long-term potentiation](/mechanisms/long-term-potentiation) (LTP) and long-term depression (LTD) through its effects on actin cytoskeleton and AMPA receptor trafficking [26]. [@bonhoeffer2003]
Myelination: In oligodendrocytes and Schwann cells, PLEKHG5 regulates the actin cytoskeleton changes required for proper myelin sheath formation and maintenance [27]. [@sheng2002]
--- [@nave2018]
PLEKHG5 mutations cause autosomal recessive intermediate Charcot-Marie-Tooth disease type C (CMTRIC), characterized by childhood-onset progressive distal muscle weakness and atrophy, sensory loss, and foot deformities [5]. The disease typically presents in the first decade of life with delayed motor milestones and progresses to involve proximal muscles in adulthood. Nerve conduction studies show intermediate slowing (motor nerve conduction velocities 25-45 m/s), reflecting both axonal degeneration and demyelination [28]. [@shy2005]
Pathogenic Mechanisms: PLEKHG5 mutations in CMT impair Rho GTPase signaling in Schwann cells and neurons, disrupting cytoskeletal dynamics essential for peripheral nerve function [29]. Defective PLEKHG5 function leads to abnormal myelination, impaired axonal transport, and secondary axonal degeneration [30]. [@harel2014]
PLEKHG5 variants have been identified in ALS patients, though less frequently than in CMT [6]. These variants may act as disease modifiers, influencing age of onset or rate of progression. The mechanisms linking PLEKHG5 to motor neuron degeneration include: [@suter2007]
Axonal Transport Defects: PLEKHG5 deficiency impairs cytoskeletal dynamics required for axonal transport of vesicles, organelles, and signaling complexes [31]. [@perlson2010]
Dendritic Spine Loss: Altered PLEKHG5 signaling contributes to the characteristic loss of [dendritic spines](/cell-types/dendritic-spines) in cortical and spinal motor neurons [32]. [@williams2007]
Neuroinflammation: PLEKHG5 in [microglia](/entities/microglia) and [astrocytes](/entities/astrocytes) regulates inflammatory responses that contribute to motor neuron injury [33]. [@liao2018]
Muscle Innervation: Impaired PLEKHG5 function at the neuromuscular junction may contribute to denervation [34]. [@martinez2013]
Peripheral Neuropathy: PLEKHG5 variants have been reported in other forms of hereditary neuropathy beyond classical CMT [35]. [@hattori2013]
Neurodevelopmental Disorders: PLEKHG5 is expressed during brain development, and variants may contribute to neurodevelopmental disorders including intellectual disability and autism [36]. [@liu2015]
--- [@brandt2007]
PLEKHG5 interacts with multiple regulatory proteins that modulate its activity and localization. The protein localizes to the plasma membrane through PH domain-phosphoinositide interactions, bringing it into proximity with its GTPase substrates [15]. Scaffold proteins including IQGAP and FilGAP regulate PLEKHG5 signaling by bringing it into complex with specific GTPases and effectors [37][38].
Modulating PLEKHG5 activity represents a potential therapeutic strategy for neurodegenerative diseases:
Rho GTPase Modulators: Several FDA-approved drugs target Rho GTPase signaling (e.g., fasudil for cerebral vasospasm), and similar approaches could be adapted for PLEKHG5-related disorders [39].
GEF Activity Inhibitors: Small molecules inhibiting RhoGEF activity are under development for various indications [40].
Gene Therapy: For PLEKHG5-related CMT, gene replacement or editing approaches could restore normal protein function [41].
PLEKHG5 expression in blood or CSF may serve as a biomarker for peripheral nerve injury or motor neuron disease [42]. Additionally, PLEKHG5 genetic variants could inform disease risk prediction.
PLEKHG5 sequencing is included in NGS panels for hereditary neuropathy and ALS. For suspected CMTRIC, comprehensive testing includes sequencing of PLEKHG5 and related genes [43]. Genetic counseling is recommended given the autosomal recessive inheritance pattern.
CMTRIC patients with PLEKHG5 mutations typically present with childhood-onset distal weakness, sensory loss, and foot deformities (pes cavus, hammertoes). Progression is slow but can lead to significant disability [5].
ALS patients with PLEKHG5 variants present with typical ALS phenotype but may have earlier onset or more rapid progression in some cases [6].
The study of Plekhg5 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
The following diagram shows the key molecular relationships involving plekhg5 discovered through SciDEX knowledge graph analysis:
The following diagram shows the key molecular relationships involving plekhg5 discovered through SciDEX knowledge graph analysis: